



# Designing & Evaluating Clinical Algorithms for STI Case Management

Francis J. Ndowa  
WHO  
RHR/STI





# Session outline

- STI case management
- STI syndromic case management
- Algorithms development
- Implementation
- Algorithms evaluation
- Exercise (Group + presentation)



# Objectives of an STI programme

- to interrupt the transmission of sexually transmitted infections
- to prevent development of disease, complications and sequelae
- to reduce the risk of HIV infection



# Objectives of STI case management

- to provide appropriate antimicrobial therapy in order to:
  - obtain cure of infection
  - decrease infectiousness
- to limit or prevent high risk behaviour
- to ensure that sexual partners are treated in order to interrupt the chain of transmission



# STI case management: Requirements

- Accurate diagnosis
- Treat at first encounter
- Rapid cure with effective drugs
- Simplicity
- Integrated approach
- Condom promotion
- Education/Counselling
- Partner notification



# Comprehensive STI case management

- History taking and symptoms
- Examination
- Treatment
  - Client and partner(s)



# Factors that influence patients' choice of facility

- **Accessibility**
  - proximity
  - affordability
- **Acceptability**
  - non-stigmatising
  - non-judgmental staff attitudes
  - convenient opening hours
  - affordable fees
- **Quality of services**
  - efficiency of service delivery
  - competence of staff
  - effectiveness of therapy
  - availability of drugs



# Diagnostic approaches to STI

## Disadvantages

- clinical }
  - neither sensitive nor specific
  - mixed infections cannot be detected
- laboratory }
  - simple tests not available/do not exist
  - cost: existing rapid test expensive
  - delay: results not readily available
- syndromic }
  - costs of over-treatment
  - side-effects of over-treatment





# STI syndromic case management: definition

- Syndromic diagnosis:  
identification of consistent group of symptoms and easily recognised signs (syndromes)
- Syndromic treatment:  
treat the main organisms responsible for causing the syndrome




# How syndromic management works

Through a series of flow-charts:

- guides the health-care worker through the correct identification and treatment of an STI-associated syndrome
- offers a package of comprehensive care from history taking, examination, to counselling/education on risk reduction and partner notification



# Urethral Discharge



Source WHO, 2003



# Urethral discharge (with microscope)

Patient complains of urethral discharge (dysuria)

Examine: milk urethra if necessary

Discharge confirmed?

No

Ulcer(s) present?

No

- Educate
- Counsel if needed
- Promote/provide condoms

Yes

**Microscopy**

Yes

Use appropriate flow chart

Intracellular diplococci present?

Yes

No

- **Treat for gonorrhoea and Chlamydia**
- Educate, Counsel etc.
- Return if necessary

- **Treat for chlamydia only**
- Educate, counsel etc.
- Return if necessary

Source WHO, 1995



# Genital ulcers

Patient complains of genital sore or ulcer

Examine

Ulcer present?

No

Vesicular or recurrent lesion(s) present?

No

Yes

Yes

- **Treat for syphilis and chancroid**
- Educate and Counsel etc.
- Advise to return in 7 days


- **Management of herpes**
- Educate
- Counsel if needed
- Promote/provide condoms

- Educate
- Counsel if needed
- Promote/provide condoms

Source WHO, 1995



# Genital Ulcer



- Educate and counsel
- Promote condom use and provide condoms
- Offer HIV counselling and testing if both facilities are available

**TREAT FOR HSV2.  
TREAT FOR SYPHILIS IF INDICATED<sup>1</sup>**

**TREAT FOR SYPHILIS AND CHANCROID.  
TREAT FOR HSV2<sup>2</sup>**

- Educate and counsel
- Promote condom use and provide condoms
- Offer HIV counselling and testing if both facilities are available
- Ask patient to return in 7 days

- Educate and counsel
- Promote condom use and provide condoms
- Manage and treat partner
- Offer HIV counselling and testing if both facilities are available

<sup>1</sup>indications for syphilis treatment  
- RPR positive; and  
- No recent syphilis treatment  
<sup>2</sup> Treat for HSV2 where prevalence is 30% or higher, or adapt to local conditions


Source WHO, 2003





# Botswana

## Changes in the aetiology of GUD 1993 - 2002




Source: M. Rahman, ISSTD, Ottawa 2003



# Botswana

## Aetiology of genital ulcer disease 2002




Source: M. Rahman, ISSTD, Ottawa 2003





# Current genital ulcer algorithm in Botswana

Complaint sores/ulcer on genitals



Sensitivity	33%
Specificity	45%
Over treatment rate	99%
Infections missed	67%
Cost per infection Tx.	\$88.0



# Piloted genital ulcer algorithm in Botswana

Complaint of sores/ulcer on genitals

Only vesicles present?

Yes

Treat for **herpes**  
return in 7 days if symptoms persist

No

Ulcer found on genitals

No

Other STI?

Yes

Treat for syphilis, chancroid and **herpes**  
Ask patient to return in 7 days

Ulcer healed

Yes

Other STI?

No

Ulcer improved but not healed continue therapy for 7 days and return

Ulcer not improved  
**REFER**

Sensitivity

99%

Specificity

13%

Over treatment rate

36%

Infections missed

1%

Cost per infection Tx.

\$4.5



# Vaginal discharge (with speculum only)

Patient complains of vaginal discharge (vaginal itching)

Lower abdominal tenderness or partner symptomatic or specific risk factors positive?

No

Yes

Treat for cervical infection plus vaginal infection according to speculum examination findings

Speculum and bimanual vaginal exam

Mucopus from cervix?

Profuse vaginal discharge?

Curd-like vaginal discharge?

No discharge?

Cervical motion tenderness present?

- **Treat for cervical infections**
- Educate, Counsel
- Return if necessary

- **Treat for trichomonas and bacterial vaginosis**
- 4 C's
- Return if necessary

- **Treat for candida**
- Educate/counsel
- Return if necessary

Educate  
Counsel if needed  
Promote/provide condoms

Use flow chart for lower abdominal pain



# Vaginal discharge (with speculum and microscope)



Patient complains of vaginal discharge (vaginal itching)

Lower abdominal tenderness or partner symptomatic or specific risk factors positive?

Yes

Treat for cervical infection plus vaginal infection according to speculum exam findings

No

Speculum + bimanual vaginal examinations + wet mount/gram stain microscopy of vaginal specimen

Mucopus from cervix?

Trichomonas?

Candida?

No discharge?

Cervical motion tenderness present?

• **Treat for cervical infections**  
• Educate, Counsel  
• Return if necessary

• **Treat for trichomonas and bacterial vaginosis**  
• 4 C's  
• Return if necessary

• **Treat for candida**  
• Educate/counsel  
• Return if necessary

Educate  
Counsel if needed  
Promote/provide condoms

Use flow chart for **low abdominal pain**





# Vaginal discharge (without microscope, using risk score)

Patient complains of vaginal discharge  
(vaginal itching)

Lower abdominal tenderness  
or partner symptomatic  
or **risk score positive**\*?

No

- Treat for **vaginal** infections
- Educate
- Counsel if needed
- Promote/provide condoms

Yes

- Treat for **cervical** and **vaginal** infections
- Educate and counsel
- Return if necessary

\* **Risk score = any 2 of**

- age <21
- single
- >1 partner in last 3/12
- new partner in last 3/12

Source WHO, 1995



# Vaginal discharge

Patient complains of vaginal discharge, vulval itching or burning

Take history and examine  
Assess risk<sup>1</sup>

Abnormal vaginal discharge or vulval erythema?

No

Any other genital disease?

No

- Educate and counsel
- Promote condom use and provide condoms
- Offer HIV counselling and testing if both facilities are available

Yes

Use appropriate flowchart for additional treatment

Yes

Lower abdominal tenderness?

No

High GC/CT prevalence setting<sup>2</sup> or risk assessment positive?

No

**TREAT FOR BACTERIAL VAGINOSIS AND TRICHOMONAS VAGINALIS**

Yes

Use flowchart for lower abdominal pain

**TREAT FOR GONOCOCCAL INFECTION, CHLAMYDIA TRACHOMATIS, BACTERIAL VAGINOSIS AND TRICHOMONAS VAGINALIS.**

Yes

Vulval oedema/curd-like discharge, erythema, excoriations present?

No

- Educate and counsel
- Promote condom use and provide condoms
- Offer HIV counselling and testing if both facilities are available

Yes

**TREAT FOR CANDIDA ALBICANS**

<sup>1</sup> Risk factors need adaptation to local social, behavioural and epidemiological situation.

<sup>2</sup> The determination of high prevalence levels needs to be made locally.



# Vaginal discharge: Bimanual & speculum, with or without microscope

Patient complains of vaginal discharge, vulval itching or burning

Take history and examine patient (external, speculum and bimanual)  
Assess risk<sup>1</sup>  
Perform wet mount microscopy of vaginal specimen for TV and yeast cells (optional)

Lower abdominal tenderness or cervical motion tenderness present?

Yes

Use flowchart for lower abdominal pain

No

Cervical mucopus or erosions or High GC/CT prevalence setting<sup>2</sup> or risk assessment positive?

No

**TREAT FOR BACTERIAL VAGINOSIS AND TRICHOMONAS VAGINALIS**

Yes

**TREAT FOR GONOCOCCAL INFECTION, CHLAMYDIA TRACHOMATIS, BACTERIAL VAGINOSIS AND TRICHOMONAS VAGINALIS.**

Vulval oedema/curd-like discharge, vulval erythema, excoriations present or yeast cells on microscopy?

No

- Educate and counsel
  - Promote condom use and provide condoms
  - Offer HIV counselling and testing if both facilities are available
- 
- Manage and treat partner if cervical mucopus present
  - Manage and treat partner if microscopy demonstrates TV

Yes

**TREAT FOR CANDIDA ALBICANS**

CHL GEN

<sup>1</sup> Risk factors need adaptation to local social, behavioural and epidemiological situation

<sup>2</sup> The determination of high prevalence levels needs to be made locally

Source WHO, 2003



# Vaginal discharge: Bimanual, speculum & microscope

Patient complains of vaginal discharge, vulval itching or burning

Take history and examine patient (external, speculum and bimanual)  
Assess risk<sup>1</sup>

Lower abdominal tenderness or cervical motion tenderness present?

Yes

Use flowchart for lower abdominal pain

No

Cervical mucopus or erosions or High GC/CT prevalence setting<sup>2</sup> or risk assessment positive?

No

Yes

**TREAT FOR GONOCOCCAL INFECTION AND CHLAMYDIA TRACHOMATIS**  
plus vaginal infection according to speculum and microscope examination findings

Perform wet mount/Gram stain microscopy of vaginal specimen

Motile trichomonads

Clue cells seen plus pH>4.5 or KOH positive?

Budding yeasts or pseudohyphae seen

No abnormal findings

**TREAT FOR TRICHOMONAS VAGINALIS**

**TREAT FOR BACTERIAL VAGINOSIS**

**TREAT FOR CANDIDA ALBICANS**

Educate and counsel • Promote condom use and provide condoms • Manage and treat partner • Offer HIV counselling and testing if both facilities are available • Ask patient to return if necessary

<sup>1</sup>Risk factors need adaptation to local social, behavioural and epidemiological situation  
<sup>2</sup> The determination of high prevalence levels needs to be made locally





# IMPLEMENTATION

## 1. Pre-requisite information

- Prevalence of STIs
- STI treatment-seeking behaviour
- Treatment practices & counselling (PI6 & PI7)
- Level of (and capacity for) training of implementers
- Drug policy, ordering and distribution system
- Stakeholders involvement
- Review of literature (need 'evidence criteria')



# IMPLEMENTATION

## 2. Conduct or analyse aetiological studies

- Genital ulcer syndrome
- Male genital discharge syndrome
- Female genital discharge (+/- risk-assessment)
- Resistance patterns

## 3. Assess if there is need to depart from WHO or existing national/regional algorithms

## 4. Adaptation for high/low risk environment

- high/low prevalence area
- high risk/low risk populations



# IMPLEMENTATION

## 5. Determine the role of the laboratory

- for case management (and monitoring as ‘test of cure’)
- for screening and case finding
- for supporting research

## 6. Determine levels of use/capacity

- will influence flowchart design & need pre-testing
- will influence choice of drugs
- depends on referral patterns



# IMPLEMENTATION

## 7. Drug selection: criteria for the choice of drugs (WHO, 2003)

- efficacy (cure at least 95% of those infected)
- safety
- cost
- compliance and acceptability
- availability (e.g. at primary health care level)
- use in pregnancy
- broad spectrum (can cover co-existing infections)
- resistance unlikely to occur rapidly



# IMPLEMENTATION

8. Printing and distribution (and translation) of flowcharts

9. Training

- post-service institutional training
- on-the-job training
- pre-service training
- what cadres to train

10. Drug procurement and distribution



# IMPLEMENTATION

## 11. Monitoring and Supervision

- WHAT?
  - clinical outcomes on returnees and non-returnees
    - cured/ improved/ treatment failures
    - referral/ no follow-up
  - *Neisseria gonorrhoeae* susceptibility
  - aetiological surveys
  - quality of care (PI6, PI7)
- HOW (universal? sentinel sites? standardised protocols? consensual workshops)
- WHEN?

## 12. Evaluation scheme



# Monitoring & Evaluation

Evaluate programme and interventions

Assess the epidemic and the response

Train and supervise

Advocate for STI inclusion in the health-care agenda

Adopt and adapt evidence-based interventions

Strengthen STI programme management and intervention activities



# Evaluation of Algorithms

- Validity: sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV)
- Feasibility: infrastructure, personnel
- Cost: direct and indirect costs, cost/effectiveness
- Acceptability: health care provider, STI patient, programme manager





# Validity of an algorithm (1):

Comparison between:

- Outcome of the algorithm
  - Simulation studies
  - Real outcome in field conditions
- Gold standard diagnosis
  - Laboratory tests



## Validity of an algorithm (2)

- Calculation: 2 x 2 table
  - sens, spec, PPV, NPV
- Interpretation: 2 x 2 table
  - correctly treated, over treated, missed infections